Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. - Concepedia

Concepedia

Publication | Closed Access

Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial.

223

Citations

21

References

1993

Year

D G Tubergen, Gerald S. Gilchrist, Richard T. O’Brien, Peter F. Coccia, Harland N. Sather, Mary J. Waskerwitz, G. Denman Hammond

Journal of Clinical Oncology

Abstract

Delint improves the EFS rate of children with ALL and intermediate presenting features. Maintenance IT MTX can be safely substituted for CXRT for presymptomatic CNS therapy in children with intermediate-risk characteristics less than 10 years of age.

References

	Year	Citations

Page 1